NeOnc Technologies Holdings, Inc. (NTHI)
NGM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -5.7M | -6.9M | -13.6M | -7.0M |
| Net Income | -5.7M | -8.6M | -15.5M | -8.8M |
| Diluted EPS | $-0.30 | $-0.45 | $nan | $-0.38 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 20K | 70K | 83K | 40K |
| Operating Income | -2.8M | -8.1M | -7.1M | -58.2M |
| Net Income | -3.0M | -14.9M | -11.9M | -62.1M |
| Diluted EPS | $-0.16 | $-0.80 | $-0.63 | $-3.20 |